In 1998, we reported a randomized study comparing intraosseous (i.o.) and i.v. transplantation of allogeneic haematopoietic stem cells. 1 The conclusion of that study was that i.o. infusion of BM cells could be done safely.
In our 1998 study, 38 patients were transplanted with BM from sibling donors (i.o. (n = 8), i.o.+ i.v. (n = 10) and i.v. (n = 20)). The majority of the patients had acute or chronic leukaemia (33/38). The transplantation procedure with conditioning, immunosuppression and supportive care has been described previously in detail. 2 In the patients receiving i.o. infusion, median follow-up time was 19.3 (18.4-20.5) years and in the i.v. group the corresponding value was 19.0 (18.4-20.6) years. In the initial report, there were no differences in time to reach a neutrophil count of 40.5 × 10 9 /L, in time to reach platelet engraftment of 430 × 10 9 /L, in transfusions of erythrocytes or platelets, in probability of acute GVHD of grades II-IV, or in chronic GVHD. 1 TRM, probability of relapse and leukaemia-free survival at 2 years were not significantly different between the two groups. The i.o. group needed fewer days with total parenteral nutrition (P = 0.03). There were no patients with bacteraemia during the first 30 days in the i.o. group, as opposed to six patients in those given BM grafts i.v. (P = 0.02). Because of the low risk of bacteraemia with i.o. infusion, we decided to include this approach in later patients. However, four consecutive patients who received i.o. BM infusion after this trial had ended all developed coagulase-negative staphylococcal septicaemia. After that, all patients received their graft i.v. Most importantly, technetium scintigraphy using antigranulocyte monoclonal Ab showed that there was no difference in activity in the skeleton, and distribution of marked BM granulocytes was the same after i.o. or i.v. infusion.
In the almost 20-year follow-up, the probability of chronic GVHD was similar in the i.o. group and the i.v. group ( Figure 1a) . TRM was also about the same in the two groups: 33% at 20 years in the i.o. patients and 30% in those receiving their grafts i.v. (Figure 1b ). The probability of relapse was similar in the two groups (Figure 2a) , as was survival (Figure 2b) . None of the patients in the trial have developed a secondary malignancy, and at present there are seven patients surviving in the i.o. arm and six patients in the i.v. arm.
Our study was conducted in the early years of mobilized PBSC allogeneic haematopoietic SCT. 3 In the study, the whole volume of BM grafts, usually 41L , was infused via bilateral i.o. routes in the posterior iliac crest. Although we used i.v. analgesia with morphine hydrochloride before transplantation, all patients experienced some discomfort or mild pain during the infusion. A secondary aim, to speed up time to engraftment of neutrophils or platelets, was not achieved.
In recent years, a murine study comparing i.o. and i.v. infusion of stem cells has shown a 15-fold potential increase in the homing capacity of i.o. transplanted stem cells compared to i.v. transplantation. 4 This mouse study is in contrast to our experience with a similar distribution of BM cells after i.o. or i.v. infusion. 1 Better donor cell engraftment in a rat model by i.o. (as opposed to i.v. infusion of the BM) was also reported by Klimczak et al. 5 Thus, the results in humans and rats have also been contradictory. Rapid reconstitution of the hematolymphoid system and amelioration of autoimmune diseases were also reported after i.o. injection of BM cells in mice. 6 Furthermore, i.o. infusion of the graft has shown induction of persistent donor-specific tolerance even with sublethal conditioning, extended engraftment without immunosuppression and prevention of GVHD. [6] [7] [8] IRamirez et al. 9 reported on a study of i.o. infusion of one or two umbilical cord blood transplants. The units were randomized to i.o. or i.v. injection. In that study, neither was time to hematopoietic recovery shorter, nor was chimerism skewed towards the i.o. unit (four patients from the i.o. unit and five patients from the i.v. unit). Five patients had grade II acute GVHD and two patients grade III, which was not different from retrospective controls receiving both units by the i.v. route. Because there was no difference in engraftment, and no possibility of finding this even with enrollment of additional patients, the study was terminated early.
Aiming to reduce the graft failure problem after cord blood transplantation, Frassoni et al.
10 studied i.o. infusion of cord blood cells. Their study included 75 patients and indicated that there was a high rate of successful engraftment (96%) and a low incidence of acute GVHD. Three patients had very severe chronic GVHD. The authors' interpretation of the results was that i.o. transplantation also overcomes the problems of graft failure. The probability of acute GVHD of grade II was 14% and none of the patients experienced acute GVHD of grades III-IV. These encouraging results have so far not been confirmed by other clinical studies.
The shortcomings of the two prospective randomized studies are that there were relatively few patients included, 38 and 10, in the two studies, respectively. 1, 9 None of the studies showed any benefit of i.o. versus i.v. infusion. The study by Frassoni et al. is contradictory and favours i.o. infusion, but has the limitation of being a non-randomized, non-confirmed pilot study. However, it includes a fair number, 75 patients.
We conclude that after long-term observation of i.o. infusion of BM stem cells that the procedure is safe and that the results are similar to those from the current clinical practice of i.v. infusion. In humans, there is no difference in distribution with i.o. infusion and with i.v. infusion, and an i.o. infusion is essentially given i.v. and does not bypass the lung. The long-term consequences and experiences of i.o. infusion of BM (as compared to i.v. infusion) would most likely be the same after PBSC or cord blood i.o. SCT. A well-conducted prospective randomized study is required to prove whether i.o. infusion of cord blood grafts has any advantage over i.v. infusion. 
